GAIMS Journal of Medical Sciences (Jun 2023)

Post-splenectomy Posterior Reversible Encephalopathy Syndrome in a β-Thalassemia Major child with Evans Syndrome

  • Rekha Thaddanee,
  • Ekta Thacker,
  • Shamim Morbiwala,
  • Vinisha Makhijani,
  • Bhushan M Warpe,
  • Vishva Sureja

DOI
https://doi.org/10.5281/zenodo.8031301
Journal volume & issue
Vol. 3, no. 2
pp. 29 – 33

Abstract

Read online

Patients with β-Thalassemia Major are at risk of alloimmunization and autoimmunization because they need regular multiple blood transfusions. Here we are reporting a case of an 8 years old male child, known case of β-thalassemia major, who developed autoimmune pancytopenia, known as Evans syndrome, and post-splenectomy neurological complication Posterior Reversible Encephalopathy Syndrome (PRES). Evans syndrome (ES) is a rare autoimmune disorder characterized by autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP) with or without immune neutropenia. There is no established evidence-based treatment. Steroids are used as a first-line therapy. Intravenous immunoglobulin is used as a life-saving therapy in severe cases. Rituximab and splenectomy are used as a second-line therapy. PRES is linked with hypertension. Characteristic clinical features of PRES are headache, blurring of vision, seizures, altered consciousness, cortical blindness or transient motor deficit.

Keywords